Deepinder Goyal apologises to doctors following a public dispute over his Temple product, after earlier comments drew criticism and the controversy was framed by some outlets as a “scam” row. In the new reporting, Goyal says the criticism he received was directed at influencers rather than medical professionals.
Before the apology, Goyal had defended Temple by pointing to a reported $30 million investment, a 14-day return policy, and plans for further scientific validation. The two sources presented the same core sequence: a defence of Temple’s legitimacy, followed by backlash, and then an apology focused on relations with doctors. Both articles describe the same rationale and the same shift in tone, with the later emphasis on outreach and acknowledgement toward the medical community.
Overall, the differences are mainly in framing: the earlier position is characterised through Temple’s business and validation claims, while the later update foregrounds the apology and how Goyal categorises who he believes should have been the primary audience for the criticism.